Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)

This Phase 2 study is testing a combination of hepatic arterial infusion chemotherapy (HAIC — chemo delivered directly into the liver's blood supply), durvalumab (an immunotherapy drug), and lenvatinib (a targeted drug) for patients with advanced bile duct cancer (intrahepatic cholangiocarcinoma) who have not yet received systemic treatment. **You may be eligible if...** - You have a confirmed diagnosis of intrahepatic cholangiocarcinoma (bile duct cancer inside the liver) - Your cancer is unresectable (cannot be surgically removed) or has spread to other organs - You have not received prior systemic (whole-body) cancer treatment **You may NOT be eligible if...** - You have severe liver dysfunction (Child-Pugh C), significant jaundice, hepatic encephalopathy, refractory fluid buildup (ascites), or hepatorenal syndrome - You have a severe blood clotting disorder - You have active hepatitis or serious infection that cannot be treated alongside the study treatment - You have severe malnutrition or multiple organ failure Talk to your doctor to see if this trial is right for you.